Chad Savage
Internal Medicine · Brighton, MINPI 1912977869
Payments from drug & device makers
Across 175 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$600
- AstraZeneca$227
- Exact Sciences$225
- AbbVie$218
- Pfizer$130
- plus $373 from 10 others
What the payments were for
- Food & beverage$3,13398%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 78 | $1,424 |
| Lilly USA, LLC | 36 | $600 |
| AstraZeneca | 12 | $227 |
| Exact Sciences | 11 | $225 |
| AbbVie | 11 | $218 |
| Pfizer | 6 | $130 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| GSK | 3 | $55 |
| Novartis | 3 | $51 |
| Edwards Lifesciences | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Medline Industries LP | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$114
How this compares
$3,197 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $28,535 |
| JardianceEmpagliflozin | 13 | $21,239 |
| MounjaroTirzepatide | 15 | $15,665 |
| RybelsusSemaglutide | 13 | $14,493 |
| XareltoRivaroxaban | 15 | $8,487 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $7,113 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,055 |
| Levothyroxine Sodium | 133 | $1,526 |
| Atorvastatin Calcium | 66 | $1,263 |
| Rosuvastatin Calcium | 56 | $1,049 |
| Propranolol Hcl ErPropranolol Hcl | 14 | $1,042 |
| Losartan Potassium | 54 | $816 |
| Ezetimibe | 25 | $796 |
| Duloxetine Hcl | 15 | $662 |
| Metoprolol Succinate | 40 | $651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $130 | $28,53523 claims |
| Lilly USA, LLCMounjaro | $600 | $15,66515 claims |
| Novo NordiskRybelsus | $1,424 | $14,49313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Brighton
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.